CN-122005584-A - Application of gastrodin in preparation of medicine for relieving muscular atrophy caused by dexamethasone

Abstract

The invention provides application of gastrodin in preparation of a medicament for relieving muscular atrophy caused by dexamethasone, and belongs to the technical field of medicines. The invention discovers that the gastrodin has remarkable relieving effect on the muscle atrophy induced by dexamethasone for the first time, and researches show that the gastrodin can remarkably improve the holding power of the mice with reduced muscle atrophy, relieve gastrocnemius muscular atrophy, increase the average muscle fiber cross section area of gastrocnemius, inhibit the expression of related proteins Fbx and MURF1, promote the expression of related proteins MyHC and MyoD of muscle development, and the gastrodin does not influence the natural recovery of the weight of the mice with reduced muscle atrophy, thereby having good medication safety.

Inventors

• Song Tongxing
• Wan Fangyan
• MEI ZHINAN

Assignees

• 华中农业大学

Dates

Publication Date

20260512

Application Date

20260330

Claims (6)

1. 1. Application of gastrodin in preparing medicine for relieving muscular atrophy caused by dexamethasone is provided.
2. 2. The use according to claim 1, wherein the effective concentration of gastrodin is 8mg/kg to 200mg/kg body weight.
3. 3. The use according to claim 1, wherein the gastrodin is prepared as an injectable formulation using PBS as solvent.
4. 4. The use according to claim 1, wherein the medicament is an injectable or an oral formulation.
5. 5. The use according to claim 4, wherein the injectable formulation is an intraperitoneal injection, an intravenous injection, an intramuscular injection.
6. 6. The use according to claim 4, wherein the oral preparation is a tablet, a drop pill, a granule, an oral liquid, a powder, a capsule.

Description

Application of gastrodin in preparation of medicine for relieving muscular atrophy caused by dexamethasone Technical Field The invention belongs to the technical field of medicines, and particularly relates to application of gastrodin in preparation of a medicament for relieving muscular atrophy caused by dexamethasone. Background Dexamethasone, which is a clinically common glucocorticoid, has various pharmacological actions such as anti-inflammatory, antiallergic and antishock effects, and is widely used for the treatment of autoimmune diseases, inflammatory diseases and the like. However, long-term or large-dose use of the plug Mi Songyi induces muscular atrophy, which is manifested by reduced muscle weight, reduced muscle function, myofibrosis and the like, and becomes an important adverse reaction in clinical application, so that the life quality of patients is seriously affected, and no specific medicine for relieving the muscular atrophy exists at present. Gastrodin is the main active ingredient of rhizoma Gastrodiae, and has been proved by existing researches to have effects of tranquilizing, relieving convulsion, improving microcirculation, and protecting nerve, and has wide application in treating nervous system diseases, but has not found its application in relieving hormone-induced muscular atrophy. According to the invention, animal experiments prove that the gastrodin can effectively relieve muscle atrophy caused by dexamethasone, improve muscle functions, does not influence the natural recovery of body weight, has good safety, provides a new effective medicament for relieving the muscle atrophy caused by dexamethasone, and simultaneously expands the medical application field of the gastrodin. Disclosure of Invention The invention aims to provide a new application of gastrodin in preparation of a medicament for relieving muscular atrophy caused by dexamethasone. In order to achieve the above purpose, the invention adopts the following technical scheme: Application of gastrodin in preparing medicine for relieving muscular atrophy caused by dexamethasone is provided. In the application, the effective concentration of the gastrodin is preferably 8 mg/kg-200 mg/kg body weight. Preferably, the effective concentration of the gastrodin is 50 mg/kg-100 mg/kg body weight. In the above application, preferably, the gastrodin is prepared into injection preparation by using PBS as a solvent. For use as described above, preferably the medicament is an injectable or an oral formulation. Further, preferably, the injection preparation is an intraperitoneal injection, an intravenous injection or an intramuscular injection. Further, preferably, the oral preparation is a tablet, a drop pill, a granule, an oral liquid, a powder and a capsule. For the application as described above, the gastrodin is used for relieving gastrocnemius atrophy caused by dexamethasone, improving the muscle grasping power of mice with reduced muscle wilt, and increasing the average muscle fiber cross-sectional area of gastrocnemius of the mice with reduced muscle wilt. The invention has the beneficial effects that: The invention provides a new application of gastrodin, and application of gastrodin in preparing a medicament for relieving muscular atrophy caused by dexamethasone, so as to fill in a gap of a medicament for clinically relieving hormone-induced muscular atrophy and expand the medical application range of gastrodin. The invention discovers that gastrodin can obviously improve the muscle function of mice with reduced muscle atrophy, improve the gripping power, specifically relieve gastrocnemius muscular atrophy, increase the cross-sectional area of muscle fibers and improve the symptom of muscular atrophy in both form and function. The gastrodin can relieve muscular atrophy and simultaneously does not influence the natural recovery of the weight of the mice with muscular atrophy, so that the gastrodin has good medication safety and no obvious organism growth inhibition effect. Drawings FIG. 1 is a schematic diagram of experimental technique route in example 1 of the present invention. FIG. 2 is a graph showing the statistical result of daily weight change in mice in example 1. FIG. 3 is a graph showing the results of the grip test for each group of mice in the experiment of the present invention. Fig. 4 is a graph showing the results of muscle weight measurements of mice in each group in the present invention, wherein a is the weight of tibialis anterior, B is the weight of quadriceps femoris, C is the weight of gastrocnemius, D is the total weight of the muscle, P <0.05 indicates P <0.01, and the differences between groups are statistically significant. Fig. 5 is a graph showing the results of quantitative analysis of the expression and development of gastrocnemius atrophy and related proteins in mice in each group in the experiment of the present invention, wherein a is a western blot protein expression electrophoresis graph,